- Home
- BGLC vs LTRY Comparison
BGLC vs LTRY Comparison
Compare BGLC & LTRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- LTRY
- Stock Information
- Founded
- BGLC 2017
- LTRY 2015
- Country
- BGLC Malaysia
- LTRY United States
- Employees
- BGLC N/A
- LTRY N/A
- Industry
- BGLC Medical Specialities
- LTRY Computer Software: Prepackaged Software
- Sector
- BGLC Health Care
- LTRY Technology
- Exchange
- BGLC Nasdaq
- LTRY Nasdaq
- Market Cap
- BGLC 7.6M
- LTRY N/A
- IPO Year
- BGLC N/A
- LTRY N/A
- Fundamental
- Price
- BGLC $0.37
- LTRY $0.51
- Analyst Decision
- BGLC
- LTRY
- Analyst Count
- BGLC 0
- LTRY 0
- Target Price
- BGLC N/A
- LTRY N/A
- AVG Volume (30 Days)
- BGLC 117.9K
- LTRY 61.6K
- Earning Date
- BGLC 11-20-2024
- LTRY 11-29-2024
- Dividend Yield
- BGLC N/A
- LTRY N/A
- EPS Growth
- BGLC N/A
- LTRY N/A
- EPS
- BGLC N/A
- LTRY N/A
- Revenue
- BGLC $9,183,168.00
- LTRY $5,723,382.00
- Revenue This Year
- BGLC N/A
- LTRY N/A
- Revenue Next Year
- BGLC N/A
- LTRY N/A
- P/E Ratio
- BGLC N/A
- LTRY N/A
- Revenue Growth
- BGLC N/A
- LTRY 125.44
- 52 Week Low
- BGLC $0.31
- LTRY $0.51
- 52 Week High
- BGLC $3.39
- LTRY $7.01
- Technical
- Relative Strength Index (RSI)
- BGLC 32.80
- LTRY 35.84
- Support Level
- BGLC $0.38
- LTRY $0.51
- Resistance Level
- BGLC $0.49
- LTRY $0.57
- Average True Range (ATR)
- BGLC 0.02
- LTRY 0.03
- MACD
- BGLC -0.01
- LTRY 0.01
- Stochastic Oscillator
- BGLC 5.94
- LTRY 0.00
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.